L Parker Gregg, Aaron Perkins, Hui Yang, Christine Vu, Vijay Nambi, Wolfgang C Winkelmayer, S Susan Hedayati, Sankar D Navaneethan, Carlos A Alvarez
{"title":"Association of Second Anti-hypertensive Agent with Outcomes in People with CKD on ACEi/ARB Therapy.","authors":"L Parker Gregg, Aaron Perkins, Hui Yang, Christine Vu, Vijay Nambi, Wolfgang C Winkelmayer, S Susan Hedayati, Sankar D Navaneethan, Carlos A Alvarez","doi":"10.1681/ASN.0000001313","DOIUrl":"https://doi.org/10.1681/ASN.0000001313","url":null,"abstract":"<p><strong>Background: </strong>Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are first-line treatment for hypertension in chronic kidney disease (CKD). However, guidelines do not recommend subsequent medication classes if additional blood pressure-lowering effect is desired.</p><p><strong>Methods: </strong>This target trial emulation using national outpatient data from the Veterans Health Administration from January 1, 2010, to December 31, 2016, included adults with non-dialysis CKD stages G1-G5 on an ACEi/ARB who initiated treatment with a second antihypertensive medication, classified as a thiazide diuretic, loop diuretic, calcium channel blocker, or β-blocker. Outcomes included composite cardiovascular events (fatal or nonfatal myocardial infarction or stroke, hospitalization for heart failure, coronary revascularization), all-cause death, and composite kidney outcomes (dialysis initiation, kidney transplantation, sustained creatinine doubling). Clinically important characteristics were included as covariates in the analysis.</p><p><strong>Results: </strong>Of 150,369 individuals already on ACEi/ARB treatment, 45,836 (30%) were prescribed a thiazide diuretic, 17,589 (12%) a loop diuretic, 33,172 (22%) a calcium channel blocker, and 53,772 (36%) a β-blocker. Those receiving thiazide diuretics and calcium channel blockers had the highest baseline blood pressure. Those receiving loop diuretics were more likely to have more advanced CKD or heart failure. Over a median (IQR) follow-up of 1282 (621, 1979) days, compared to thiazide diuretics, cardiovascular event risk was higher for calcium channel blockers, aHR 1.18 (95% CI 1.15-1.22), β-blockers, aHR 1.63 (95% CI 1.58-1.67), and loop diuretics, aHR 1.97 (95% CI 1.90-2.04). Composite kidney outcomes were also higher with calcium channel blockers, aHR 1.42 (95% CI 1.33-1.52), β-blockers, aHR 1.13 (95% CI 1.06-1.21), and loop diuretics, aHR 1.98 (95% CI 1.83-2.15).</p><p><strong>Conclusions: </strong>Adding a thiazide diuretic rather than a calcium channel blocker, β-blocker, or loop diuretic on top of ACEi/ARB treatment was associated with favorable clinical outcomes among people with CKD.</p>","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":" ","pages":""},"PeriodicalIF":9.7,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149407532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jin-Gu Lee, Jun-Yi Zhu, Xiaoxuan Fan, Patricio E Ray, Zhe Han
{"title":"Endoplasmic Reticulum Membrane Insertion of APOL1 Risk Alleles Disrupts Calcium Homeostasis and Is Mitigated by Autophagic Clearance.","authors":"Jin-Gu Lee, Jun-Yi Zhu, Xiaoxuan Fan, Patricio E Ray, Zhe Han","doi":"10.1681/ASN.0000001319","DOIUrl":"https://doi.org/10.1681/ASN.0000001319","url":null,"abstract":"<p><strong>Background: </strong>Apolipoprotein 1 (APOL1) risk alleles (G1 and G2) are major genetic drivers of APOL1-associated kidney disease in populations of African ancestry. Prior studies implicated membrane-associated channel activity and ion dysregulation in APOL1 cytotoxicity, but how APOL1 risk alleles engage intracellular membranes, disrupt endoplasmic reticulum calcium, and are handled by quality-control pathways remains incompletely defined.</p><p><strong>Methods: </strong>We used a split-green fluorescent protein topology system to visualize and quantify APOL1 membrane insertion and domain-deletion mutants to define structural requirements for insertion and toxicity. Endoplasmic reticulum calcium was monitored using a genetically encoded fluorescent, endoplasmic reticulum-specific calcium indicator. APOL1 degradation was assessed using autophagy and proteasome modulators, immunoblotting, and LC3 colocalization. In vivo relevance was tested in transgenic Drosophila nephrocytes expressing human APOL1 alleles with or without dietary rapamycin.</p><p><strong>Results: </strong>APOL1 inserted robustly into the endoplasmic reticulum membrane under basal cellular conditions, and its pore-forming and membrane-addressing domains contributed strongly to insertion and cytotoxicity. APOL1-G1 and APOL1-G2 showed greater endoplasmic reticulum membrane insertion than APOL1-G0, accompanied by greater endoplasmic reticulum calcium depletion. These findings support a model in which risk allele-associated misfolding exposes hydrophobic regions that promote aberrant endoplasmic reticulum membrane engagement. APOL1 accumulated after autophagy inhibition, decreased after rapamycin treatment, and localized to LC3-positive autophagosomal structures, whereas proteasomal inhibition did not accumulate APOL1 nor induce its toxicity. Rapamycin reduced APOL1 protein levels, improved cell viability, and mitigated risk allele-induced nephrocyte hypertrophy and filtration dysfunction in vivo.</p><p><strong>Conclusions: </strong>These findings identified enhanced endoplasmic reticulum membrane insertion, endoplasmic reticulum calcium depletion, and autophagy-lysosomal clearance as linked features of APOL1 risk allele toxicity.</p>","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":" ","pages":""},"PeriodicalIF":9.7,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149407533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carla M Nester, Andrew S Bomback, Gema Ariceta, Yahsou Delmas, Bradley P Dixon, Daniel P Gale, Larry A Greenbaum, Seung Hyeok Han, Nicole Isbel, Christoph Licht, Antonio Mastrangelo, Masashi Mizuno, Maria Izabel Neves de Holanda, Matthew C Pickering, Giuseppe Remuzzi, Nicole C A J Van De Kar, Marina Vivarelli, Patrick D Walker, Dean Wallace, Daniel Zecher, Moglie Le Quintrec, Yael Borovitz, Nabil Melhem, Eli Khankin, Zhongshen Wang, Elena Surova, Johan Szamosi, Fadi Fakhouri
{"title":"Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN.","authors":"Carla M Nester, Andrew S Bomback, Gema Ariceta, Yahsou Delmas, Bradley P Dixon, Daniel P Gale, Larry A Greenbaum, Seung Hyeok Han, Nicole Isbel, Christoph Licht, Antonio Mastrangelo, Masashi Mizuno, Maria Izabel Neves de Holanda, Matthew C Pickering, Giuseppe Remuzzi, Nicole C A J Van De Kar, Marina Vivarelli, Patrick D Walker, Dean Wallace, Daniel Zecher, Moglie Le Quintrec, Yael Borovitz, Nabil Melhem, Eli Khankin, Zhongshen Wang, Elena Surova, Johan Szamosi, Fadi Fakhouri","doi":"10.1681/ASN.0000001296","DOIUrl":"https://doi.org/10.1681/ASN.0000001296","url":null,"abstract":"<p><strong>Background: </strong>In VALIANT (phase 3 trial), pegcetacoplan (C3/C3b inhibitor) demonstrated significant proteinuria reduction at week 26 versus placebo (prespecified primary endpoint), stable eGFR, and glomerular C3 clearance in participants with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis.</p><p><strong>Methods: </strong>In VALIANT's 26-week randomized controlled period, participants (≥12 years) received subcutaneous pegcetacoplan (n=63) or placebo (n=61) twice weekly plus supportive care. During the 26-week open-label period, all received pegcetacoplan. Here we report prespecified exploratory endpoints during the open-label period.</p><p><strong>Results: </strong>Fifty-nine participants who received pegcetacoplan and 55 who received placebo in the randomized controlled period completed the open-label period. At week 52, the pegcetacoplan-to-pegcetacoplan group maintained the 26-week proteinuria reduction (mean [95% confidence interval (CI)] urine protein-to-creatinine ratio changes from baseline: week 26, -67.1% [-74.9 to -56.8]; week 52, -67.2% [-75.8 to -55.4]). The placebo-to-pegcetacoplan group showed proteinuria changes of 3.2% (-9.6 to 17.9) (26 weeks of placebo), and -53.9% (-64.5 to -40.1) (26 weeks of pegcetacoplan [pegcetacoplan start [week 26] to week 52; post hoc]). In the pegcetacoplan-to-pegcetacoplan group, eGFR changes from baseline (least-squares [LS] mean [95% CI]) were -1.2 mL/min/1.73 m2 (-5.6 to 3.2) (week 26) and -3.7 mL/min/1.73 m2 (-8.9 to 1.6) (week 52). In the placebo-to-pegcetacoplan group, mean (95% CI) eGFR changes from baseline were -7.9 (-11.7 to -4.2) (week 26) and -4.7 (-9.1 to -0.3) (week 52); week-26-to-52 change was +3.0 (-1.0 to 7.1) (post hoc). Post hoc analyses of 52 weeks of pegcetacoplan (n=118) showed proteinuria reduction (geometric mean [95% CI] -63.0% [-69.9 to -54.7]) and eGFR stabilization (LS mean [95% CI] change from realigned baseline, +0.1 [-3.8 to 4.0] mL/min/1.73 m2). No new safety concerns were identified. No encapsulated meningococcal infections, deaths, or allograft losses occurred.</p><p><strong>Conclusions: </strong>Results demonstrate sustained proteinuria reduction and eGFR stabilization after 1 year of pegcetacoplan.</p>","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":" ","pages":""},"PeriodicalIF":9.7,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149407535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Daniel Edmonston, Benjamin Catanese, Naga Sai Akhil Reddy Gogula, Maxfield Brody, Rebecca D Sullenger, Samantha Kaplan, Sophia Wang, Mykenzi Davis-Cowart, Monica Leyva, Ebele Umeukeje, Javier Morales, Julienne Kirk, Adrian F Hernandez, Katherine R Tuttle, Javed Butler, Neha Pagidipati
{"title":"Implementation Strategies to Improve CKD Testing and Delivery of Guideline-Directed Medical Therapy: A Scoping Review.","authors":"Daniel Edmonston, Benjamin Catanese, Naga Sai Akhil Reddy Gogula, Maxfield Brody, Rebecca D Sullenger, Samantha Kaplan, Sophia Wang, Mykenzi Davis-Cowart, Monica Leyva, Ebele Umeukeje, Javier Morales, Julienne Kirk, Adrian F Hernandez, Katherine R Tuttle, Javed Butler, Neha Pagidipati","doi":"10.1681/ASN.0000001324","DOIUrl":"https://doi.org/10.1681/ASN.0000001324","url":null,"abstract":"<p><strong>Background: </strong>Chronic kidney disease (CKD) remains underdiagnosed and undertreated despite substantial cardiovascular and mortality risks. Guidelines recommend annual testing with estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) in at-risk populations, and a growing number of guideline-directed medical therapies (GDMT) improve kidney and cardiovascular outcomes in CKD. We conducted a scoping review of controlled implementation studies to identify effective strategies for improving CKD testing and GDMT delivery and define priorities for future implementation trials.</p><p><strong>Methods: </strong>Following a registered protocol and PRISMA extension for Scoping Reviews (PRISMA-ScR) guidance, we searched MEDLINE, Embase, and the Web of Science Core Collection from database inception through June 9, 2026 for English-language prospective controlled studies. Eligible studies compared an implementation strategy with usual care or another control condition. We charted study characteristics and outcomes using standardized templates and synthesized findings by objective, strategy, setting, design, and target population.</p><p><strong>Results: </strong>We included 26 reports from 24 studies (N=7 testing, N=17 treatment). Six of 7 studies increased CKD testing, with the largest gains from patient-directed home testing and automated laboratory ordering paired with clinical decision support. However, increased testing seldom translated into increased CKD diagnosis or GDMT prescriptions. Of implementation efforts focused on CKD treatment, only 5 of 17 studies increased GDMT prescribing. Passive, single-touch strategies, including isolated alerts, one-time prompts, and registries without active outreach, rarely changed prescribing. In contrast, longitudinal strategies that incorporated pharmacist- or advanced practice provider-led management, nephrologist-supported multidisciplinary care, or proactive registry-based outreach more consistently increased GDMT exposure and sometimes improved intermediate clinical outcomes.</p><p><strong>Conclusions: </strong>Among 24 prospective controlled studies, patient-directed home testing and automated laboratory ordering paired with clinical decision support increased CKD testing, but increased testing seldom led to CKD diagnosis or GDMT prescribing. Only 5 of 17 treatment studies increased GDMT prescribing, all through longitudinal, team-based care.</p>","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":" ","pages":""},"PeriodicalIF":9.7,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149407534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Generalizability of Target Trial-Emulated Hemodiafiltration Evidence: Stable European Cohorts and East Asian Real-World Constraints.","authors":"Daijun Hu, Yuewu Tang","doi":"10.1681/ASN.0000001297","DOIUrl":"https://doi.org/10.1681/ASN.0000001297","url":null,"abstract":"","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":" ","pages":""},"PeriodicalIF":9.7,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149386956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pathogenic Gd-IgA1: Redefining the Role of Galactose-Deficient IgA1 in IgA Nephropathy.","authors":"Yoshihito Nihei, Yusuke Suzuki","doi":"10.1681/ASN.0000001328","DOIUrl":"https://doi.org/10.1681/ASN.0000001328","url":null,"abstract":"<p><p>IgA nephropathy is the most common primary glomerular nephritis worldwide and remains one of the leading causes of kidney failure. Although IgA nephropathy is a heterogeneous disease, glomerular deposition of galactose-deficient IgA1 (Gd-IgA1) is considered a pathological feature shared across the disease. This pathological hallmark underpins the multihit hypothesis of IgA nephropathy and has driven the development of therapies targeting Gd-IgA1 production, several of which have recently demonstrated clinical efficacy and received regulatory approval. These advances provide a timely opportunity to re-evaluate the role of Gd-IgA1 in the pathogenesis of IgA nephropathy. Notably, analysis of longitudinal changes in serum Gd-IgA1 levels and proteinuria reported in recent therapeutic trials raises the possibility that only a subset of circulating Gd-IgA1, rather than the entire circulating Gd-IgA1 pool, may drive glomerular inflammation leading to hematuria and/or proteinuria in IgA nephropathy. In this review, we propose the concept of \"pathogenic Gd-IgA1\" to describe this disease-relevant subset and highlight three potential features: a mucosal origin, molecular properties that promote selective mesangial deposition, and the capacity to form immune complexes and activate the complement system. This conceptual framework may deepen our understanding of IgA nephropathy pathogenesis, help optimize the use of emerging therapies, and facilitate the development of novel therapies that selectively target pathogenic Gd-IgA1.</p>","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":" ","pages":""},"PeriodicalIF":9.7,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149379508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Autoimmunity at the Slit Diaphragm: More Targets, More Questions.","authors":"Andrea Angeletti, Paolo Cravedi","doi":"10.1681/ASN.0000001304","DOIUrl":"https://doi.org/10.1681/ASN.0000001304","url":null,"abstract":"","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":" ","pages":""},"PeriodicalIF":9.7,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149379507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Authors' Reply: Sphingolipids and Death in Hemodialysis: A Data Inconsistency and Unaddressed Competing Risk.","authors":"Benjamin Lidgard, Paul N Jensen, Leila R Zelnick","doi":"10.1681/ASN.0000001227","DOIUrl":"10.1681/ASN.0000001227","url":null,"abstract":"","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":" ","pages":"2585-2586"},"PeriodicalIF":9.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13743000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Remote Ischemic Preconditioning for Prevention of Contrast-Associated Acute Kidney Injury following Coronary Angiography or Percutaneous Coronary Intervention.","authors":"Indu Ramachandra Rao, Ganesh Paramasivam, Shravana Acharya, Sunil Ravindranath, Vishal Shanbhag, Mahidhar Jeedigunta, Attur Ravindra Prabhu","doi":"10.1681/ASN.0000001145","DOIUrl":"10.1681/ASN.0000001145","url":null,"abstract":"<p><strong>Key points: </strong>Remote ischemic preconditioning reduced the risk of contrast-associated AKI in patients undergoing coronary angiography or percutaneous coronary intervention. The benefits of remote ischemic preconditioning were consistent across coronary angiography, percutaneous coronary intervention, diabetes, and CKD subgroups. Remote ischemic preconditioning probably reduced in-hospital major adverse cardiovascular events, although there was no significant impact on 30-day kidney and cardiac outcomes.</p><p><strong>Background: </strong>Remote ischemic preconditioning may prevent contrast-associated AKI and have cardioprotective effects in patients undergoing coronary angiographic procedures; however, results have been inconsistent. The aim of this systematic review and meta-analysis was to evaluate whether remote ischemic preconditioning lowers the risk of contrast-associated AKI and improves short-term kidney and cardiac outcomes in patients undergoing coronary angiography or percutaneous coronary intervention (PCI).</p><p><strong>Methods: </strong>We performed a comprehensive literature search using PubMed, Embase, and the Cochrane Central Register of Controlled Trials from inception through December 6, 2025. Randomized controlled trials (RCTs) comparing remote ischemic preconditioning with either sham remote ischemic preconditioning or usual care for kidney and/or cardiac outcomes in patients undergoing coronary angiography or PCI were included. Two independent reviewers screened studies, extracted data, and assessed risk of bias using the Cochrane Risk of Bias 2.0 tool. Outcomes studied were contrast-associated AKI, need for dialysis, in-hospital mortality, in-hospital major adverse cardiovascular events (MACE), 30-day mortality, 30-day MACE, and major adverse kidney events at 30 days. Data were pooled using a random-effects model and expressed as risk ratios (RR) with 95% confidence intervals (CI). Certainty of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation approach.</p><p><strong>Results: </strong>Of the 5532 records identified, 36 RCTs encompassing 10,923 patients were included in this systematic review. Compared with sham remote ischemic preconditioning or usual care, remote ischemic preconditioning significantly reduced contrast-associated AKI (RR, 0.54; 95% CI, 0.45 to 0.65; 30 RCTs, 5078 participants; high-certainty evidence). Remote ischemic preconditioning probably reduced in-hospital MACE (RR, 0.51; 95% CI, 0.26 to 0.98; four RCTs, 1266 participants; moderate-certainty evidence). There were no differences in the need for dialysis, in-hospital mortality, 30-day mortality, and 30-day MACE.</p><p><strong>Conclusions: </strong>Remote ischemic preconditioning reduced the risk of contrast-associated AKI and in-hospital MACE in patients undergoing coronary angiography or PCI.</p>","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":" ","pages":"2483-2494"},"PeriodicalIF":9.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13742987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148042816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ian B Stanaway, Ines P D Costa, Simon J Davies, Jeffrey Perl, Mark Lambie, Johann Morelle, Gail P Jarvik, Arsh K Jain, Jonathan Himmelfarb, Olof Heimburger, David W Johnson, James Pirkle, Bruce Robinson, Peter Stenvinkel, Angela Yee-Moon Wang, Olivier Devuyst, Rajnish Mehrotra
{"title":"Correction to: Genetic Variation and Ultrafiltration with Peritoneal Dialysis: A Genome-Wide Association Study.","authors":"Ian B Stanaway, Ines P D Costa, Simon J Davies, Jeffrey Perl, Mark Lambie, Johann Morelle, Gail P Jarvik, Arsh K Jain, Jonathan Himmelfarb, Olof Heimburger, David W Johnson, James Pirkle, Bruce Robinson, Peter Stenvinkel, Angela Yee-Moon Wang, Olivier Devuyst, Rajnish Mehrotra","doi":"10.1681/ASN.0000001222","DOIUrl":"10.1681/ASN.0000001222","url":null,"abstract":"","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":" ","pages":"2589-2590"},"PeriodicalIF":9.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13742980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148562256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}